Results 31 to 40 of about 10,061 (158)

Variability of response on prophylactic prasugrel for endovascular treatment of intracranial aneurysms: Clinical implications.

PLoS ONE, 2023
Background and purposeProphylactic prasugrel for endovascular treatment of intracranial aneurysms has been introduced and increased, but HTPR (high on-treatment platelet reactivity) or LTPR (low on-treatment platelet reactivity) of prasugrel is not ...
Noah Hong, Seung Bin Kim, Hee-Jin Yang, Young-Je Son   +3 more
doaj   +1 more source

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Management of patients with non–ST‐segment–elevation acute coronary syndrome (NSTE‐ACS) is based on 2020 European Society of Cardiology guidelines, which recommend the preferential use of prasugrel over ticagrelor. Because the selection of the
Mustafa Yildirim, Matthias Mueller‐Hennessen, Barbara Ruth Milles, Moritz Biener, Hauke Hund, Norbert Frey, Evangelos Giannitsis, Christian Salbach   +7 more
doaj   +1 more source

Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

Marshall Journal of Medicine, 2019
Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI.
Ahmed Amro, Kanaan Mansoor, Mohammad Amro, Amal Sobeih, Obadah Aqtash, Hisham Hirzallah, Alaa Gabi , Madhulika Urella, Waseem Ahmed , Sandra Shenouda, Rameez Sayyed   +10 more
doaj   +1 more source

Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication

Haematologica, 2015
In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor like prasugrel is prescribed for one year. Here, we investigated how the hemostatic function of platelets recovers after discontinuation of prasugrel ...
Constance C. F. M. J. Baaten, Leo F. Veenstra, Rick Wetzels, Johanna P. van Geffen, Frauke Swieringa, Susanne M. de Witt, Yvonne M. C. Henskens, Harry Crijns, Sven Nylander, J. J. J. van Giezen, Johan W. M. Heemskerk, Paola E. J. van der Meijden   +11 more
doaj   +1 more source

Interaction of Operator−Patient Sex on Peri‐Procedural Treatments and Major Coronary Outcomes After Percutaneous Coronary Intervention

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background There are limited data evaluating the association between operator−patient sex, and outcomes in patients undergoing percutaneous coronary intervention (PCI). Methods We included 138,112 consecutive PCI procedures in patients presenting with acute coronary syndrome (ACS) in England and Wales, 2017−2020.
Sharon A. Ayayo, Vicky P. Taxiarchi, Angela Jerath, Evangelos Kontopantelis, Sonya N. Burgess, Sarah Zaman, Mamas A. Mamas   +6 more
wiley   +1 more source

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?

Рациональная фармакотерапия в кардиологии, 2020
Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment. The new generation of inhibitors of P2Y12 platelet receptors (prasugrel and ticagrelor) provide more pronounced platelet inhibition than clopidogrel.
T. M. Uskach, A. S. Tereshchenko
doaj   +1 more source

CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches

Clinical Pharmacology &Therapeutics, EarlyView.
Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no‐function alleles.
Rachael M. Stone, Glenda Hoffecker, April Schultz, Brittney H. Davis, Salma A. Bargal, Amber L. Beitelshees, Nihal El Rouby, Madeline Norris, Kevin J. Rodriguez, Nita Limdi, Larisa H. Cavallari, Craig R. Lee   +11 more
wiley   +1 more source

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis

Frontiers in Cardiovascular Medicine, 2022
BackgroundThis meta-analysis mainly aimed to compare the impact of prasugrel and ticagrelor on platelet reactivity (PR) in patients with acute coronary syndrome (ACS).MethodsWe searched four electronic databases to identify randomized controlled trials ...
Lulu Dai, Jiawei Xu, Yuerong Jiang, Keji Chen   +3 more
doaj   +1 more source

Update on the Pathophysiology, Aetiology and Management of Central Sleep Apnoea

Respirology, EarlyView.
ABSTRACT Central sleep apnoea (CSA) of the periodic breathing type occurs during the transition between wakefulness and stage 1 and 2 non‐REM sleep. In adults at sea level, it occurs most commonly due to advanced heart failure (HF) or chronic opioid use and in ~5% of obstructive sleep apnoea patients initiating CPAP.
Sahan D. Chandrasekara, Matthew T. Naughton   +1 more
wiley   +1 more source

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

Journal of Hematology & Oncology, 2013
Background Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients with SCD ...
Wun Ted, Soulieres Denis, Frelinger Andrew L, Krishnamurti Lakshmanan, Novelli Enrico M, Kutlar Abdullah, Ataga Kenneth I, Knupp Charles L, McMahon Lillian E, Strouse John J, Zhou Chunmei, Heath Lori E, Nwachuku Chuke E, Jakubowski Joseph A, Riesmeyer Jeffrey S, Winters Kenneth J   +15 more
doaj   +1 more source